Briscoe Laboratory

Transplantation is widely recognized as the treatment of choice for end stage organ disease in children. Nevertheless, despite significant advances in immunosuppressive therapeutics to prevent acute rejection, long-term graft survival remains suboptimal. For most transplanted organs, the rate of decline in function has not changed in over 20 years. It has therefore become most apparent that long term success following transplantation will require greater understanding of responses that both promote and inhibit chronic allograft rejection. There is also a huge need to develop mechanistic biomarkers to define the status of the alloimmune response and indices of graft injury so that new therapeutics can be developed.

Research in the Briscoe Laboratory relates to all these issues with a focus on the intragraft microenvironment, and how it functions to both promote and inhibit chronic rejection. Our studies focus on three broad areas, including: 1) how leukocyte-endothelial cell interactions and products of these interactions promote, sustain or inhibit T cell activation and allorecognition, 2) how events within the microvasculature sustain or inhibit chronic allograft rejection, and 3) the development of novel biomarkers and new therapeutics to transform clinical care and improve outcomes following transplantation. We are currently expanding our research effort into the area of inflammation resolution, and we are specifically interested in endogenous mechanisms and regulatory signaling networks of pro-resolution. Understanding these processes will allow us to develop new paradigms for anti-rejection therapeutics following transplantation.

Please visit the Briscoe Laboratory website to learn more.

Briscoe Laboratory, 2018